TRANSCODE THERAPEUTICS, INC. Research and Development Expense
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Research and Development Expense of $3.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- TRANSCODE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $3.69M, a 43.96% increase year-over-year.
- TRANSCODE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $5.11M, a 130.09% increase year-over-year.
- TRANSCODE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $5.48M, a 50.49% increase year-over-year.
- TRANSCODE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $3.16M, a 157.54% increase year-over-year.
- TRANSCODE THERAPEUTICS, INC. research and development expense for fiscal 2025 was $13.42M, a 38.28% increase from fiscal 2024.
- TRANSCODE THERAPEUTICS, INC. research and development expense for fiscal 2024 was $9.71M, a 20.85% decline from fiscal 2023.
- TRANSCODE THERAPEUTICS, INC. research and development expense for fiscal 2023 was $12.26M, a 19.85% increase from fiscal 2022.
- TRANSCODE THERAPEUTICS, INC. research and development expense for fiscal 2022 was $10.23M, a 271.55% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.69M 10-Q · filed 2026-08-14 | $8.80M 10-Q · filed 2026-08-14 | $14.28M derived: sum of 3 quarters · filed 2026-08-14 | $17.44M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.11M 10-Q · filed 2026-05-15 | $10.58M derived: sum of 2 quarters · filed 2026-05-15 | $13.74M derived: sum of 3 quarters · filed 2026-05-15 | $16.31M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $8.64M derived: sum of 2 quarters · filed 2026-04-15 | $11.20M derived: sum of 3 quarters · filed 2026-08-14 | $13.42M 10-K · filed 2026-04-15 |
| 2025-09-30 | $3.16M 10-Q · filed 2025-11-14 | $5.73M derived: sum of 2 quarters · filed 2026-08-14 | $7.95M 10-Q · filed 2025-11-14 | $11.58M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.57M 10-Q · filed 2026-08-14 | $4.79M 10-Q · filed 2026-08-14 | $8.42M derived: sum of 3 quarters · filed 2026-08-14 | $9.65M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.22M 10-Q · filed 2026-05-15 | $5.86M derived: sum of 2 quarters · filed 2026-05-15 | $7.09M derived: sum of 3 quarters · filed 2026-05-15 | $10.17M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $4.87M derived: sum of 2 quarters · filed 2026-04-15 | $7.95M derived: sum of 3 quarters · filed 2026-04-15 | $9.71M 10-K · filed 2026-04-15 |
| 2024-09-30 | $1.23M 10-Q · filed 2025-11-14 | $4.31M derived: sum of 2 quarters · filed 2025-11-14 | $6.07M 10-Q · filed 2025-11-14 | $9.43M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.08M 10-Q · filed 2025-08-14 | $4.84M 10-Q · filed 2025-08-14 | $8.20M derived: sum of 3 quarters · filed 2025-08-14 | $11.55M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.76M 10-Q · filed 2025-05-14 | $5.12M derived: sum of 2 quarters · filed 2025-05-14 | $8.47M derived: sum of 3 quarters · filed 2025-05-14 | $11.43M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $6.71M derived: sum of 2 quarters · filed 2025-04-15 | $9.67M derived: sum of 3 quarters · filed 2025-04-15 | $12.26M 10-K · filed 2025-04-15 |
| 2023-09-30 | $3.34M 10-Q · filed 2024-11-14 | $6.31M derived: sum of 2 quarters · filed 2024-11-14 | $8.90M 10-Q · filed 2024-11-14 | $11.59M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.97M 10-Q · filed 2024-08-14 | $5.56M 10-Q · filed 2024-08-14 | $8.24M derived: sum of 3 quarters · filed 2024-08-14 | $11.29M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $2.59M 10-Q · filed 2024-05-15 | $5.28M derived: sum of 2 quarters · filed 2024-05-15 | $8.32M derived: sum of 3 quarters · filed 2024-05-15 | $10.94M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.73M derived: sum of 2 quarters · filed 2024-04-01 | $8.35M derived: sum of 3 quarters · filed 2024-04-01 | $10.23M 10-K · filed 2024-04-01 |
| 2022-09-30 | $3.04M 10-Q · filed 2023-11-14 | $5.66M derived: sum of 2 quarters · filed 2023-11-14 | $7.55M 10-Q · filed 2023-11-14 | $8.83M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $2.62M 10-Q · filed 2023-08-14 | $4.50M 10-Q · filed 2023-08-14 | $5.79M derived: sum of 3 quarters · filed 2023-08-14 | $6.78M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.88M 10-Q · filed 2023-05-15 | $3.17M derived: sum of 2 quarters · filed 2023-05-15 | $4.16M derived: sum of 3 quarters · filed 2023-05-15 | $4.37M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.28M derived: sum of 2 quarters · filed 2023-03-31 | $2.49M derived: sum of 3 quarters · filed 2023-03-31 | $2.75M 10-K · filed 2023-03-31 |
| 2021-09-30 | $992.95K 10-Q · filed 2022-11-14 | $1.20M derived: sum of 2 quarters · filed 2022-11-14 | $1.47M 10-Q · filed 2022-11-14 | $1.62M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $211.75K 10-Q · filed 2022-08-15 | $475.51K 10-Q · filed 2022-08-15 | $627.33K derived: sum of 3 quarters · filed 2022-08-15 | $681.27K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $263.76K 10-Q · filed 2022-05-16 | $415.58K derived: sum of 2 quarters · filed 2022-05-16 | $469.52K derived: sum of 3 quarters · filed 2022-05-16 | $544.52K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $151.82K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $205.76K derived: sum of 2 quarters · filed 2022-03-31 | $280.76K derived: sum of 3 quarters · filed 2022-03-31 | $284.46K 10-K · filed 2022-03-31 |
| 2020-09-30 | $53.94K 10-Q · filed 2021-11-15 | $128.94K derived: sum of 2 quarters · filed 2021-11-15 | $132.64K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $75.00K 10-Q · filed 2021-08-23 | $78.70K 10-Q · filed 2021-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |